斯凯生物制药和欧药推出了位于多伦多的人工智能平台Mentis Care, 实现实时发作检测和预测分析. SK Biopharma and Eurofarma launch Mentis Care, a Toronto-based AI epilepsy platform, to enable real-time seizure detection and predictive analytics.

SK生物制药公司和巴西的欧洲农场于2025年10月20日创办了一家合资企业Mentis Care, 开发并推销AI驱动的癫痫管理平台。 SK Biopharmaceuticals and Brazil’s Eurofarma launched Mentis Care, a joint venture on October 20, 2025, to develop and market an AI-powered epilepsy management platform. 该平台使用AI驱动的EEG和可磨损技术,以便实时检测缉获、预测性分析和临床决策支持。 The platform uses AI-driven EEG and wearable technologies to enable real-time seizure detection, predictive analytics, and clinical decision support. 该企业以多伦多为基地,将在全球范围内扩展,侧重于北美和拉丁美洲,Hassan Kotob担任首席执行官。 Based in Toronto, the venture will expand globally, focusing on North and Latin America, with Hassan Kotob as CEO. 欧药公司领导业务战略和人工智能数据开发, 建立在现有的药物合作基础上. Eurofarma leads business strategy and AI data development, building on their existing drug collaboration. 该倡议标志着SK在数字健康方面的扩张,旨在通过预测性脑健康工具改善病人的安全和独立性。 The initiative marks SK’s expansion into digital health, aiming to improve patient safety and independence through predictive brain health tools.